|

Field Trip Uplists to Nasdaq | Cybin to NYSE | Mydecine MDMA Patent: Big Week For Psychedelic Stocks

ByPsychedelic Spotlight

Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!

On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.

Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.

In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.

Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/

CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/

MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#FieldTripHealth #Cybin #Mydecine

Similar Posts

  • MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)

    Listen, Videos

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
    www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Join our Newsletter (scroll to the bottom of the page and sign up):
    https://psychedelicspotlight.com/

    Follow us on Twitter:
    The Psychedelic Investor: @PSYCBiz
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @psycbiz
    @psycspotlight

    ❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
    Stay tuned for more updates!

    In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.

    MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.

    Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.

    The results were very positive, though perhaps not paradigm shifting — yet.

    The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.

    The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.

    Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.

    Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”

    In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”

    Interested in reading the article? Click here: 👇

    MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
    https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/

    #MindMed #Anxiety #MNMD

  • New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)

    Listen, Videos

    There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
    ( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
    (old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).

    Timestamps:
    0:00 – Intro
    0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
    1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
    3:16 – Analyst Coverage and Buy Ratings for CMPS
    4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
    9:17 – Numinus Wellness (NUMI) Q2 Financial Results
    11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
    12:19 – Novamind ( NM / NVMDF) doubling its clinics
    14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
    15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
    17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
    17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism

    Link to MindMed’s Project Angie Press release:
    https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

    Link to Compass Pathways Q1 financial Results date:
    https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial

    Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/

    Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
    https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html

    Link to Numinus (NUMI) Q2 2021 Financial Results:
    https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html

    Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
    https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers

    Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
    https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/

    Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
    https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/

    Link to Small Pharma ( DMT):
    https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction

    Link to Havn’s (HAVN / HAVLF) Jamaica lab:
    https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational

    Link to Nova Mentis launching a clinical study to learn more about Autism:
    https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Numi #CMPS

  • Interview with Doug Drysdale, CEO, Cybin Inc

    Listen, Podcasts

    Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.